[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557939":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":25,"studyPopulation":26,"armGroups":22,"interventions":22,"overallOfficials":22,"centralContacts":27,"locations":33,"responsibleParty":78,"collaborators":22,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":22,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":22,"maxAge":22,"enrollmentInfo":88,"targetDuration":22,"studyType":91,"phases":22,"briefSummary":92,"conditions":93,"keywords":22,"overallStatus":36,"whyStopped":22,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Safety (adverse events (AEs), serious AEs (SAEs), adverse drug reactions (ADRs), serious ADRs (SADRs), unexpected AEs\u002FADRs)","To assess safety of the study drugs for patients treated with the study drugs under the approved indication in Korea","For Imjudo will be conducted for 90 days from the first dose of the treatment. For Imfinzi will be separately conducted for 1 year from the first dose.",[14],{"measure":15,"description":16,"timeFrame":17},"Objective Response Rate(ORR)","To assess effectiveness of the study drugs for patients treated with the study drugs under the approved indication in Korea","For 1 year from the first dose of the treatment",[19],{"measure":20,"description":16,"timeFrame":17},"Disease Control Rate (DCR)",{"allocation":22,"interventionModel":22,"interventionModelDescription":22,"primaryPurpose":22,"observationalModel":23,"timePerspective":24,"maskingInfo":22},null,"COHORT","PROSPECTIVE","Primary Objective:\n\nTo assess safety of the study drugs for patients treated with the study drugs under the approved indication in Korea\n\nSecondary Objective:\n\nTo assess effectiveness of the study drugs for patients treated with the study drugs under the approved indication in Korea\n\nExploratory Objective:\n\nTo assess effectiveness of the study drugs for patients treated with the study drugs under the approved indication in Korea","Patients who initiate treatment with study drugs after the contract date for the first time.",[28],{"name":29,"role":30,"phone":31,"phoneExt":22,"email":32},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[34,45,52,59,66,71],{"facility":35,"status":36,"city":37,"state":22,"zip":22,"country":38,"countryCode":22,"cosmosGeoPoint":39,"geoPoint":44,"contacts":22},"Research Site","RECRUITING","Busan","South Korea",{"type":40,"coordinates":41},"Point",[42,43],129.03004,35.10168,{"lat":43,"lon":42},{"facility":35,"status":36,"city":46,"state":22,"zip":22,"country":38,"countryCode":22,"cosmosGeoPoint":47,"geoPoint":51,"contacts":22},"Goyang",{"type":40,"coordinates":48},[49,50],127.19731,36.21689,{"lat":50,"lon":49},{"facility":35,"status":36,"city":53,"state":22,"zip":22,"country":38,"countryCode":22,"cosmosGeoPoint":54,"geoPoint":58,"contacts":22},"Seongnam",{"type":40,"coordinates":55},[56,57],129.30505,35.48474,{"lat":57,"lon":56},{"facility":35,"status":36,"city":60,"state":22,"zip":22,"country":38,"countryCode":22,"cosmosGeoPoint":61,"geoPoint":65,"contacts":22},"Seoul",{"type":40,"coordinates":62},[63,64],126.9784,37.566,{"lat":64,"lon":63},{"facility":35,"status":67,"city":60,"state":22,"zip":22,"country":38,"countryCode":22,"cosmosGeoPoint":68,"geoPoint":70,"contacts":22},"NOT_YET_RECRUITING",{"type":40,"coordinates":69},[63,64],{"lat":64,"lon":63},{"facility":35,"status":36,"city":72,"state":22,"zip":22,"country":38,"countryCode":22,"cosmosGeoPoint":73,"geoPoint":77,"contacts":22},"Suwon",{"type":40,"coordinates":74},[75,76],127.00889,37.29111,{"lat":76,"lon":75},{"type":79,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100557939","imjudo--imfinzi-pms-100557939",false,"NCT06544629","Imjudo & Imfinzi PMS","Imjudo & Imfinzi Post-Marketing Surveillance","Inclusion criteria:\n\n1. Patients eligible for the study drugs according to the approved label in Korea\n2. Provision of signed and dated written informed consent by the patient or legally acceptable representative\n\nExclusion criteria:\n\n1. Other off-label indications according to the approved label in South Korea\n2. Current participation in any interventional trial","ALL",{"count":89,"type":90},246,"ESTIMATED","OBSERVATIONAL","Based on the re-review of new drugs article, Korean pharmaceutical act, the objectives of this study are to assess safety and effectiveness of the study drugs(Imjudo \\& Imfinzi) in a real world setting in patients who treated according to the approved indications in Korea.",[94],"Hepatocellular Carcinoma","2026-09-30",{"date":97,"type":98},"2026-10-05","ACTUAL",{"date":100,"type":98},"2025-04-14",{"date":102,"type":90},"2029-12-30",{"name":5,"class":6},6]